	Lonza announced on June 13, 2019 plans to add two production lines in an expansion of the company’s highly potent API (HPAPI) capacity at its Visp, Switzerland site to meet increased market demand. The announced investment will add two 4-m

-scale, multi-purpose lines to the company’s existing capabilities for lab- to large commercial-scale HPAPI production.

	The new lines are expected to be online by July 2020, the company reported in a press statement. In addition, the company said it plans to improve flexibility in existing production lines, to improve time-to-market and accelerate approval timelines for partners.

	The company reports that the facility will support the delivery of products from AstraZeneca portfolio under a long-term manufacturing agreement. The remaining capacity will be available to other clients.

	“We are delighted to support one of our strategic partners in securing supply of innovative therapies for the treatment of cancer patients,” said Lee Newton, vice-president and API business unit head, Lonza Pharma & Biotech. “Oncology continues as the leading indication in biopharma and we will continue to invest to meet the HPAPI development and manufacturing needs of our customers.”

API Synthesis and Manufacturing, Small Molecule

Contract Development Services

Contract Manufacturing, Drug Substance, API

Dosage Forms

Highly Potent Drugs

Outsourcing

PharmTech News

Supplier News

Two additional production lines expand Lonza’s HPAPI capacity at Visp, Switzerland facility.